UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 52,471 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 11.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 388,627 shares of the medical research company's stock after selling 52,471 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.39% of Bio-Rad Laboratories worth $127,668,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Bio-Rad Laboratories by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 1,919,808 shares of the medical research company's stock valued at $630,676,000 after purchasing an additional 12,168 shares during the last quarter. Wealthfront Advisers LLC acquired a new position in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $342,686,000. Dimensional Fund Advisors LP grew its position in shares of Bio-Rad Laboratories by 14.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 746,119 shares of the medical research company's stock valued at $245,106,000 after purchasing an additional 91,690 shares during the last quarter. Earnest Partners LLC grew its position in shares of Bio-Rad Laboratories by 2.1% in the fourth quarter. Earnest Partners LLC now owns 618,049 shares of the medical research company's stock valued at $203,035,000 after purchasing an additional 12,500 shares during the last quarter. Finally, Ariel Investments LLC grew its position in shares of Bio-Rad Laboratories by 48.0% in the fourth quarter. Ariel Investments LLC now owns 560,524 shares of the medical research company's stock valued at $184,138,000 after purchasing an additional 181,829 shares during the last quarter. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Price Performance

Shares of BIO traded up $6.54 during trading hours on Tuesday, reaching $230.32. The stock had a trading volume of 307,104 shares, compared to its average volume of 317,956. Bio-Rad Laboratories, Inc. has a 12 month low of $215.38 and a 12 month high of $387.99. The stock has a market capitalization of $6.27 billion, a PE ratio of -3.54 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. The company's 50-day moving average is $241.00 and its two-hundred day moving average is $292.31.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Bio-Rad Laboratories's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same period last year, the company earned $2.30 EPS. Research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Wall Street Analyst Weigh In

BIO has been the topic of several research reports. UBS Group decreased their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Citigroup reduced their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, Royal Bank of Canada reduced their price target on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $327.40.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.